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Heemskerk-Gerritsen et al.
1 continue to add to our
understanding of the surgical management of hered-
itary breast and ovarian cancer. In their ﬁne article,
they contribute to our knowledge of control, evalu-
ation, staging, and reconstruction.
CONTROL
The Rotterdam series is reassuring in demonstrat-
ing that bilateral prophylactic mastectomy will al-
most always prevent the development of breast
cancer. In addition to the 145 women with deﬁned
BRCA1 or two mutations followed for a median of
4.5 years, there were 32 at risk due to history, 91 with
deﬁned risk presenting with breast cancer, and 90 at
risk by history presenting with breast cancer. This
large collection adds to other studies and provides
further evidence that such prophylactic surgery for
hereditary breast and ovarian cancer radically re-
duces both the risk and anxiety, although eliminates
neither completely.
EVALUATION
The importance of careful evaluation preceding
prophylactic surgery, stressed by the authors, has
been made easier by the increasing availability of
radiologists skilled in the interpretation of MRIs of
the breast. The increased sensitivity of the technique
was initially undermined by a lack of speciﬁcity. With
growing experience, the speciﬁcity of MRI detection
has reached greater than 90%, similar to that
achieved with mammography. However, in Dr.
Christiane Kuhls series, using mammography in
BRCA mutation carriers, only one-third of their
cancers were detected, whereas MRI identiﬁed over
90%.
2 This prevents the unhappy experience of ﬁnd-
ing that surgery directed to prevention was actually
being performed as therapy.
STAGING
With careful evaluation preceding prophylactic
mastectomy there is no need for the routine inclusion
of sentinel lymph node biopsy. The authors ﬁnding
of less than 1% incidence of unanticipated invasive
cancer answers this question that has enjoyed debate
in breast evaluation rounds in recent years.
RECONSTRUCTION
The authors concluded their evaluation of recon-
struction with this sentence: ‘‘In this respect, patients
should be informed preoperatively that an optimal
cosmetic eﬀect cannot unconditionally be achieved in
just one single operation.’’ Who could ﬁnd fault with
that? They react to a concern that reconstruction may
be presented as restoration of the breasts as originally
formed. While some patients may ﬁnd that their
reconstructed breasts are closer to a common ideal
than their native breasts, many who began with near
perfection are surprised that it takes additional
tweaking after initial reconstruction to achieve
something that they can admire. Setting appropriate
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3283expectations is a task for the entire team. Many of the
complications listed by the authors, however, are true
surgical complications, not failures of aesthetic per-
fection. The team also needs to monitor these and
assure that any complication oﬀers opportunity for
improvement in technique.
Perhaps because the focus of the authors publi-
cation is on breast cancer, the emphasis on the greater
danger of ovarian cancer seems a secondary consid-
eration. With breast MRI screening, we are often able
to detect breast cancer at a minimal stage in these
women. We are still unable to detect ovarian cancer
in most instances until it has progressed to an ad-
vanced stage. By turning attention to counseling
women at hereditary risk of ovarian cancer, a dif-
ferent algorithm can emerge. Very young mutation
carriers can use birth control pills for 5 years, with a
halving of their risk of ovarian cancer. As soon as
they have had their families, salpingo-oophorectomy
can not only greatly reduce the risk of ovarian cancer,
but breast cancer risk is reduced by nearly two-thirds
if this procedure is performed prior to age 40 and
roughly halved if performed over 40 years of age.
3
This reduction can be improved by the use of
tamoxifen. The magnitude of the tamoxifen beneﬁt is
a surprising 50% reduction in risk when used by itself.
When used following oophorectomy it appears to
provide an additional 17% reduction.
4 Greater
numbers of patients so treated will be required for
more deﬁnitive statistics. It is apparent, however, that
attention to preventing the more insidious ovarian
cancer by oophorectomy dramatically reduces the
breast cancer risk.
When a woman realizes that the 80% lifetime risk
number that she has heard can be reduced to less than
40%, and that the risk over each of the next 5 years is
a tiny fraction of that, she can know great release
from the pressure to make major decisions about
prophylactic mastectomy, reconstruction, and the
timing of the two while feeling ‘‘under the gun.’’
The more that major series such as this one from
Rotterdam can inﬂuence the advice given to women
at risk, the greater their comfort in decision making,
and the greater the comfort to those providing
counsel.
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